Fernando Torres passes Chelsea medical – rumour

January 31, 2011 | by | 2 Comments

There are conflicting reports that Fernando Torres has passed his medical and will shortly become a Chelsea player.

Fernando Torres rumoured to have passed Chelsea medical

Fansite Koptalk, which correctly revealed Andy Carroll had handed in a transfer request following two rejected offers from Liverpool, tweeted the unconfirmed rumour earlier that Torres had passed his medical.

However, Spanish journalist Guillem Balague has denied that Torres has passed a medical but confirmed the clubs have agreed a £50 million fee.

If confirmed, it brings Torres’ three-and-a-half year Anfield career to a disappointing and bitter end with many Liverpool fans feeling he has let the club down by moving to a rival English club.

The 26-year-old striker initially handed in a transfer request at Liverpool on Friday after Chelsea had a £35 million bid rejected for the Spaniard.  After a weekend of negotiations, that bid is now believed to have reached £50 million.

Liverpool have agreed a club record fee with Newcastle for striker Andy Carroll while it’s also understood Blackpool’s Charlie Adam is about to have a medical with the Reds.

More to follow

Picture Credit: Nigel Wilson on Flickr

Tags: ,

Category: News

Comments (2)

Trackback URL | Comments RSS Feed

  1. scouser says:

    so the liverpool fans now know that their idol torres is not red but blue, when will football realise the only thing players love is money and nothing else, although the fans still deny it their other idol gerard was on his way to chelsea not too long ago until liverpool decided to pay much more than he’s worth, he’s just another greedy player like the rest and when thir other idol pepe reina leaves at the end of the season they might just understand that liverpool are finished as champion contenders

  2. blaqs@eircom.net says:

    Come back to anfield torres. Rayan , 6

Add your comment

Libellous and abusive comments are not allowed. Please read our House Rules

For information about privacy and cookies please read our Privacy Policy